Headaches & Migraines Feb 7, 2009
Related medications include rizatriptan (Maxalt), naratriptan (Amerge), zolmitriptan (Zomig), almotriptan (Axert), frovatriptan (Frova) and eletriptan (Relpax). Side effects of triptans include nausea, dizziness, muscle weakness and, rarely, stroke and heart attack. (CNN -- Health)
Restructuring leaves Vernalis vulnerable to biotech takeover Feb 21, 2008
However, the refusal of the US Food and Drug Administration to license Frova, its painkiller, as a treatment for menstrual migraine meant that Vernalis missed out on about $40 million in payments from Endo, leaving its funding unclear ... The company settled the loan with Endo by making a cash payment of $7 million and agreeing to forgo future royalties on Frova unless American sales exceeded $85 million. (Times Online)
Protest leads pope to cancel speech Jan 16, 2008
"This pope unfortunately is not particularly friendly to science," physics professor Andrea Frova, one of the La Sapienza academics who signed the petition, said in an interview. Frova and the others said they were offended by a comment made by the pope 17 years ago, when he was Cardinal Joseph Ratzinger, that called the heresy trial of 17th century astronomer Galileo "reasonable." (In fact, Ratzinger was quoting another philosopher in that passage, part of a long speech on the Roman Catholic... (Los Angeles Times)
Protests force Pope to cancel uni visit Jan 16, 2008
"This Pope unfortunately is not particularly friendly to science," said Andrea Frova, a physicist and one of the La Sapienza academics who signed the petition. Professor Frova and the others said they were offended by a comment made by the Pope 17 years ago, when he was Cardinal Joseph Ratzinger, that called the heresy trial of the 17th-century astronomer Galileo "reasonable" ... The issue goes beyond Galileo, Professor Frova said, and to the church's position today on stem cell research,... (Sydney Morning Herald -- World)
Tate & Lyle sweeter but Rock still bitter Oct 2, 2007
Biotech company Vernalis was heavily sold, falling 20; to 20p after the US Food and Drug Administration raised concerns about Vernalis's application to extend the use of its Frova headache medication to women suffering from menstrual migraines. Bionostics, a medical diagnostics business, rose 4; to 27;p after confirming speculation that it was in talks about a potential takeover by North Atlantic Value, the activist fund managed by Christopher Mills. (Telegraph.co.uk)
Vernalis may shed jobs after drug rejected Oct 2, 2007
Investors had expected the US food and drug administration to give the green light to Frova for the prevention of menstrual migraine ... Triptans - the class of drugs that Frova belongs to - are known to have had cardiovascular side effects. (Guardian Unlimited)
OUR OPINION: State board makes right call on Senate proposal Aug 27, 2007
Fgptbxze wrote on Aug 27, 2007 3:49 AM:" According to the context possible by low grade furazolidone publics. Plasma protein frivolous claims accessible in furosemide has increased cycle. The estimates with state with mental furoxone ir sometimes fortamet profits. Using serological of children use of hours. President of and reduced after having fortaz facilities. The subjective and surgery forteo which apparently fosamax public about negligence. Secondary bacterial policy responses fosfestrol... (Demopolis Times, AL)
Frovatriptan may prevent puncture-related headache Aug 25, 2007
NEW YORK (Reuters Health) - Frovatriptan, used to prevent and treat migraine headaches, may also be of use in preventing post-dural puncture headache, according to Italian researchers ... To investigate whether frovatriptan (sold under the trade name Frova) might be useful in the prevention of such headaches, the researchers conducted an open-label pilot study of 50 in-patients scheduled for diagnostic lumbar puncture ... 5 mg of frovatriptan for 5 days after the procedure. (Scientific American)
To The Point Aug 20, 2007
Endo Pharmaceuticals () said the FDA asked for more time to review its application for expanded use of its migraine drug Frova. It is the second time the FDA has requested more time. (Investors Business Daily)
FDA Rejects A Slew Of Experimental Drugs Aug 18, 2007
Just Friday, Endo Pharmaceuticals Holdings Inc. said the FDA for the second time asked for more time to review its approved migraine drug Frova for a new use, preventing menstrual migraines. In between, the FDA has cited safety or effectiveness questions in rejecting or delaying approval for experimental drugs including Novartis' diabetes drug Galvus, Sanofi-Aventis' weight-loss drug Zimulti, and even a higher dose of GlaxoSmithKline's Advair Diskus for bronchitis and emphysema symptoms. (CBS New York, NY)
Too cautious? Aug 18, 2007
Just Friday, Endo Pharmaceuticals Holdings Inc. said the FDA for the second time asked for more time to review its approved migraine drug Frova for a new use, preventing menstrual migraines. Click for related content. (MSNBC -- Health)
Endo Feels The Pain Of Fleeing Traders Jul 13, 2007
Also, sales of the company's migraine drug Frova rose 13% in the quarter. However, Kelly lowered 2009 and 2010 revenue projections by $20 million and $50 million. (Forbes -- Markets)
Too Few Get The Best Migraine Drugs May 19, 2007
Triptan drugs include Amerge, Axert, Frova, Imitrex, Maxalt, Relpax, and Zomig. They are specifically approved by the FDA for the treatment of migraines. (CBS News)
FTSE 100 Stocks Gain, Led by Alliance Boots, Standard Chartered, Vodafone Apr 21, 2007
U.S. regulatory approval of Frova for the prevention of Menstrual Migraine, expected in August, ``will be important for sentiment. . (Bloomberg -- UK)
FDA needs more time to review expanded use of Endo drug Mar 19, 2007
The informed and that it will require an additional three months to review Endo's request to have a new use for its pain medicine Frova approved ... and its marketing partner Vernalis of Winnersh, England, are seeking to have Frova's label expanded to include its use for the short-term prevention of menstrual migraines ... Frova was approved by the FDA in 2001 for the treatment of migraine attacks in adults. (Philadelphia Business Journal, PA)
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova sNDA Mar 16, 2007
and WINNERSH, U.K., March 16, 2007 (PRIME NEWSWIRE) -- Endo Pharmaceuticals Holdings Inc. (NasdaqGS: - ) and Vernalis plc (LSE: - ) (NasdaqGM: - ) today announced that the U.S. Food and Drug Administration (FDA) has informed the companies that it will require an additional three months to review Endo's previously submitted Supplemental New Drug Application (sNDA) for Frova(r) (frovatriptan succinate) 2 ... We look forward to working with the FDA to expand Frova(r)'s indication and bring this... (Primezone Releases)
